Press news Biocartis Group NV: Results of the Extraordinary Shareholders’ Meeting held on 2 September 2020
02 Settembre 2020 - 5:40PM
Press news Biocartis Group NV: Results of the Extraordinary
Shareholders’ Meeting held on 2 September 2020
PRESS RELEASE: REGULATED INFORMATION2 September 2020, 17:40
CEST
Results of the Extraordinary
Shareholders’ Meeting held on 2 September
2020
Mechelen, Belgium, 2 September
2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’),
an innovative molecular diagnostics company (Euronext Brussels:
BCART), held its extraordinary shareholders' meeting today.
However, there was no deliberation and voting on the items on the
agenda because the attendance quorum for the meeting was not
reached.
Biocartis will convene a second extraordinary
shareholders' meeting with the same agenda items, for which no
quorum requirement will apply.
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail
rdegrave@biocartis.comtel
+32 15 631 729 mobile +32 471 53 60
64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer. More
information: www.biocartis.com. Follow us on Twitter:
@Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
This press release is not for distribution, directly or indirectly,
in any jurisdiction where to do so would be unlawful. Any persons
reading this press release should inform themselves of and observe
any such restrictions. Biocartis takes no responsibility for any
violation of any such restrictions by any person. Please refer to
the product labeling for applicable intended uses for each
individual Biocartis product. This press release does not
constitute an offer or invitation for the sale or purchase of
securities in any jurisdiction. No securities of Biocartis may be
offered or sold in the United States of America absent registration
with the United States Securities and Exchange Commission or an
exemption from registration under the U.S. Securities Act of 1933,
as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Biocartis Group NV (EU:BCART)
Storico
Da Mag 2023 a Mag 2024